Syndesi Therapeutics, a Belgian developer of a series of novel, procognitive SV2A modulators, raised €17M in Series A financing.
The round was led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund (SRIW) and VIVES Louvain Technology Fund.
The company intends to use the funds for the clinical development of the lead compound up to early proof-of-concept in humans.
Led by Jonathan Savidge, PhD, CEO, Syndesi Therapeutics has an exclusive, worldwide license from UCB to develop and commercialize a series of novel, procognitive SV2A modulators to improve cognition in diseases such as Alzheimer’s Disease, other dementias and cognitive impairment associated with schizophrenia.
Established at the Centre d’Entreprises et d’Innovation (CEI) in Louvain-la-Neuve, the company will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium.